Alltracel advances post-operative wound care

Published: 21-Oct-2001


Alltracel, the Dublin-based biopharmaceutical research and development company, claims to have made a significant advancement in the production of its antiadhesion absorbable barrier film, which is used for the treatment of patients after surgery.

After extensive work in the laboratory, preclinical evaluation has now begun on the use of this thin, clear film to reduce the occurrence of post-operative adhesions in patients.

Post-operative adhesions (POAs) are a common cause of short and long term surgical complications, which can be significantly reduced by the insertion of a film or gel.

The market for POAs is growing rapidly, with the estimated global market likely to reach approximately $335m (€370m) by 2003.

The microfine film, derived from Alltracel's M-DOC technology platform, will form a high margin extension to the group's existing range of biocompatible M-DOC wound care surgical powders and dressings.

Trending Articles

You may also like